50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Get 1TB of Top-Rated Cloud Storage for Life for Just $112
'A Gold Storm Is Coming' (Ad)
Germany secures more gas shipments as Scholz visits Gulf
Poverty, inflation, fear: Egypt's economy pushed to brink
Finally... Some Good News (Ad)pixel
Labour conference starts with focus on 'immoral' tax cuts
Poverty and inflation: Egypt's economy hit by global turmoil
Finally... Some Good News (Ad)pixel
German leader continues Gulf tour with stops in UAE, Qatar
Fire breaks out at world's biggest produce market in Paris
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Get 1TB of Top-Rated Cloud Storage for Life for Just $112
'A Gold Storm Is Coming' (Ad)
Germany secures more gas shipments as Scholz visits Gulf
Poverty, inflation, fear: Egypt's economy pushed to brink
Finally... Some Good News (Ad)pixel
Labour conference starts with focus on 'immoral' tax cuts
Poverty and inflation: Egypt's economy hit by global turmoil
Finally... Some Good News (Ad)pixel
German leader continues Gulf tour with stops in UAE, Qatar
Fire breaks out at world's biggest produce market in Paris
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Get 1TB of Top-Rated Cloud Storage for Life for Just $112
'A Gold Storm Is Coming' (Ad)
Germany secures more gas shipments as Scholz visits Gulf
Poverty, inflation, fear: Egypt's economy pushed to brink
Finally... Some Good News (Ad)pixel
Labour conference starts with focus on 'immoral' tax cuts
Poverty and inflation: Egypt's economy hit by global turmoil
Finally... Some Good News (Ad)pixel
German leader continues Gulf tour with stops in UAE, Qatar
Fire breaks out at world's biggest produce market in Paris
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Get 1TB of Top-Rated Cloud Storage for Life for Just $112
'A Gold Storm Is Coming' (Ad)
Germany secures more gas shipments as Scholz visits Gulf
Poverty, inflation, fear: Egypt's economy pushed to brink
Finally... Some Good News (Ad)pixel
Labour conference starts with focus on 'immoral' tax cuts
Poverty and inflation: Egypt's economy hit by global turmoil
Finally... Some Good News (Ad)pixel
German leader continues Gulf tour with stops in UAE, Qatar
Fire breaks out at world's biggest produce market in Paris
NASDAQ:BOLT

Bolt Biotherapeutics - BOLT Stock Forecast, Price & News

$1.72
-0.03 (-1.71%)
(As of 09/23/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.68
$1.73
50-Day Range
$1.72
$2.61
52-Week Range
$1.39
$14.18
Volume
94,651 shs
Average Volume
127,791 shs
Market Capitalization
$64.74 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.75

Bolt Biotherapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
873.8% Upside
$16.75 Price Target
Short Interest
Healthy
3.52% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.08mentions of Bolt Biotherapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$1.60 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.25) to ($2.14) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.34 out of 5 stars

Medical Sector

268th out of 1,075 stocks

Pharmaceutical Preparations Industry

111th out of 532 stocks

BOLT stock logo

About Bolt Biotherapeutics (NASDAQ:BOLT) Stock

Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.

Receive BOLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bolt Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

BOLT Stock News Headlines

Bolt Biotherapeutics Inc Ordinary Shares
Bolt Biotherapeutics, Inc. (BOLT)
Bolt Biotherapeutics Stock Halves on Mediocre Trial Data
Why Bolt Biotherapeutics Stock Crashed Today
See More Headlines
Receive BOLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bolt Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

BOLT Company Calendar

Last Earnings
11/08/2021
Today
9/25/2022
Next Earnings (Estimated)
11/08/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:BOLT
CUSIP
09769810
Fax
N/A
Employees
91
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$16.75
High Stock Price Forecast
$45.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+873.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Net Income
$-98,590,000.00
Net Margins
-2,795.56%
Pretax Margin
-2,795.56%

Debt

Sales & Book Value

Annual Sales
$1.26 million
Book Value
$6.71 per share

Miscellaneous

Free Float
29,021,000
Market Cap
$64.74 million
Optionable
Not Optionable
Beta
1.01

Key Executives

  • Dr. Randall C. Schatzman Ph.D. (Age 67)
    CEO & Director
    Comp: $830.67k
  • Dr. Edgar G. Engleman M.D. (Age 76)
    Founder & Independent Director
    Comp: $31.58k
  • Mr. William P. QuinnMr. William P. Quinn (Age 51)
    CFO & Sec.
    Comp: $563.68k
  • Mr. Grant Yonehiro C.F.A. (Age 58)
    M.B.A., Chief Bus. Officer
    Comp: $519.98k
  • Dr. Edith A. Perez M.D. (Age 65)
    Chief Medical Officer
    Comp: $627.32k
  • Dr. David Dornan Ph.D. (Age 44)
    Advisor
    Comp: $580.08k
  • Ms. Karen L. Bergman
    VP of Communications & Investor Relations
  • Mr. Wesley Burwell
    VP & Head of HR
  • Dr. Nathan Ihle Ph.D.
    Sr. VP of Pharmaceutical Operations
  • Mr. Bruce Hug M.D.
    Ph.D., Sr. VP of Clinical Devel. & Translational Medicine













BOLT Stock - Frequently Asked Questions

Should I buy or sell Bolt Biotherapeutics stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bolt Biotherapeutics in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BOLT shares.
View BOLT analyst ratings
or view top-rated stocks.

What is Bolt Biotherapeutics' stock price forecast for 2022?

4 analysts have issued 12 month target prices for Bolt Biotherapeutics' shares. Their BOLT share price forecasts range from $4.00 to $45.00. On average, they predict the company's stock price to reach $16.75 in the next twelve months. This suggests a possible upside of 873.8% from the stock's current price.
View analysts price targets for BOLT
or view top-rated stocks among Wall Street analysts.

How have BOLT shares performed in 2022?

Bolt Biotherapeutics' stock was trading at $4.90 at the start of the year. Since then, BOLT stock has decreased by 64.9% and is now trading at $1.72.
View the best growth stocks for 2022 here
.

When is Bolt Biotherapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our BOLT earnings forecast
.

How were Bolt Biotherapeutics' earnings last quarter?

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) announced its quarterly earnings data on Monday, November, 8th. The company reported ($0.63) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.75) by $0.12. The firm had revenue of $0.75 million for the quarter, compared to analysts' expectations of $1.50 million. Bolt Biotherapeutics had a negative net margin of 2,795.56% and a negative trailing twelve-month return on equity of 40.31%.

What other stocks do shareholders of Bolt Biotherapeutics own?
When did Bolt Biotherapeutics IPO?

(BOLT) raised $150 million in an initial public offering on Friday, February 5th 2021. The company issued 8,800,000 shares at $16.00-$18.00 per share. Morgan Stanley, SVB Leerink, Stifel and Guggenheim Securities acted as the underwriters for the IPO.

What is Bolt Biotherapeutics' stock symbol?

Bolt Biotherapeutics trades on the NASDAQ under the ticker symbol "BOLT."

Who are Bolt Biotherapeutics' major shareholders?

Bolt Biotherapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (1.44%), Assenagon Asset Management S.A. (0.74%), Millennium Management LLC (0.51%), Russell Investments Group Ltd. (0.26%), Marquette Asset Management LLC (0.17%) and State Street Corp (0.13%). Insiders that own company stock include Edgar Engleman, Holdings A/S Novo, Randall C Schatzman, Vivo Capital Fund Viii, LP and William P Quinn.
View institutional ownership trends
.

How do I buy shares of Bolt Biotherapeutics?

Shares of BOLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bolt Biotherapeutics' stock price today?

One share of BOLT stock can currently be purchased for approximately $1.72.

How much money does Bolt Biotherapeutics make?

Bolt Biotherapeutics (NASDAQ:BOLT) has a market capitalization of $64.74 million and generates $1.26 million in revenue each year. The company earns $-98,590,000.00 in net income (profit) each year or ($2.61) on an earnings per share basis.

How can I contact Bolt Biotherapeutics?

Bolt Biotherapeutics' mailing address is 900 CHESAPEAKE DRIVE, REDWOOD CITY CA, 94063. The official website for the company is www.boltbio.com. The company can be reached via phone at 650-665-9295 or via email at sarah.mccabe@sternir.com.

This page (NASDAQ:BOLT) was last updated on 9/25/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.